{
    "name": "enzalutamide",
    "comment": "Rx",
    "other_names": [
        "Xtandi"
    ],
    "classes": [
        "Antineoplastics",
        "Antiandrogens"
    ],
    "source": "https://reference.medscape.com/drug/xtandi-enzalutamide-999769",
    "pregnancy": {
        "common": [
            "Safety and efficacy not established in females",
            "Drug should not be handled by females who are or may become pregnant"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Based on animal reproductive studies and mechanism of action, enzalutamide may cause fetal harm and loss of pregnancy",
                    "There are no human data on use in pregnant females",
                    "In animal reproduction studies, oral administration of enzalutamide in pregnant mice during organogenesis caused adverse developmental effects at doses lower than the maximum recommended human dose"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the final dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on animal studies, may impair fertility in males of reproductive potential"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Not indicated for use in females; unknown whether distributed in breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Seizure occurred in patients receiving enzalutamide in randomized clinical trials; advise patients of risk of engaging in activities where sudden loss of consciousness could cause serious harm to themselves or others; permanently discontinue therapy in patients who develop seizure during treatment",
                "Posterior reversible encephalopathy syndrome (PRES) reported with use; discontinue therapy in patients who develop PRES",
                "Hypersensitivity reactions, including edema of the face, tongue, or lip have been observed; pharyngeal edema reported in postmarketing cases; advise patients who experience any symptoms of hypersensitivity to temporarily discontinue treatment and promptly seek medical care; permanently discontinue drug for serious hypersensitivity reactions",
                "In clinical studies, ischemic heart disease occurred; monitor for signs and symptoms of ischemic heart disease; optimize management of cardiovascular risk factors (eg, hypertension, diabetes, or dyslipidemia); discontinue treatment for Grade 3-4 ischemic heart disease",
                "Falls and fractures occurred; evaluate patients for fracture and fall risk; monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents; routine bone density assessment and treatment of osteoporosis with bone-targeted agents were not performed in the studies",
                "Safety and efficacy not established in females (see Pregnancy)"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Strong CYP2C8 inhibitors",
                        "The coadministration of this drug with gemfibrozil (a strong CYP2C8 inhibitor) increases plasma concentrations of enzalutamide plus N-desmethyl enzalutamide, which may increase the incidence and severity of adverse reactions of the drug",
                        "Avoid coadministration of with strong CYP2C8 inhibitors; if the coadministration with a strong CYP2C8 inhibitor cannot be avoided, reduce the dosage of this drug",
                        "Strong CYP3A4 Inducers",
                        "The coadministration of this drug with rifampin (a strong CYP3A4 inducer and a moderate CYP2C8 inducer) decreases plasma concentrations of enzalutamide plus N-desmethyl enzalutamide, which may decrease the efficacy of the drug",
                        "Avoid coadministration of this drug with strong CYP3A4 inducers; if the coadministration with a strong CYP3A4 inducer cannot be avoided, increase the dosage of this drug",
                        "Effect of enzalutamide on other drugs",
                        "This drug is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer; coadministration of this drug decreases concentrations of certain CYP3A4, CYP2C9, or CYP2C19 substrates which may reduce efficacy of these substrates",
                        "Avoid coadministration of this drug with certain CYP3A4, CYP2C9, or CYP2C19 substrates for which a minimal decrease in concentration may lead to therapeutic failure of the substrate",
                        "If coadministration cannot be avoided, increase dosage of these substrates in accordance with their prescribing information; in cases where active metabolites are formed, there may be increased exposure to active metabolites",
                        "Caution if coadministered with narrow therapeutic index drugs that are substrates of the aforementioned CYP isoenzymes"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of artemether/lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with strong CYP3A4 inducers can result in decreased serum concentrations and loss of antimalarial efficacy"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cariprazine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cariprazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is responsible for the formation and elimination of cariprazine's active metabolites. The effect of CYP3A4 inducers on cariprazine exposure has not been evaluated and the net effect is unclear."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cobimetinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration. Strong or moderate CYP3A inducers may decrease cobimetinib systemic exposure by >80% and reduce its efficacy."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "doravirine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of doravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of doravirine with a strong CYP3A inducer may decrease doravirine plasma concentrations and/or effects. Potential for loss of virologic response and possible resistance to doravirine. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elbasvir/grazoprevir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of elbasvir/grazoprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic effect of elbasvir/grazoprevir may be reduced if coadministered with strong CYP3A inducers and is therefore contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "enzalutamide decreases levels of elvitegravir/cobicistat/emtricitabine/tenofovir DF by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May lead to loss of virologic response and possible resistance."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fostemsavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of fostemsavir (prodrug) with strong CYP3A4 inducers significantly decreases temsavir (active moiety) plasma concentrations, which may lead to loss of virologic response and resistance."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil will increase the level or effect of enzalutamide by  decreasing metabolism. Contraindicated. Increased enzalutamide exposure may increase risk of seizures; if co-administration is considered necessary, dose of enzalutamide should be reduced"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lenacapavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of lenacapavir with strong CYP3A inducers is contraindicated. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inducers is contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lopinavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lorlatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of lorlatinib with strong CYP3A inducers is contraindicated. Discontinue the strong CYP3A inducer for 3 plasma half-lives before initiating lorlatinib."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lumacaftor/ivacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A inducers have minimal effect on lumacaftor exposure, but decreased ivacaftor exposure (AUC) by 57%. This may reduce the effectiveness of lumacaftor/ivacaftor. Therefore, coadministration is not recommended."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with strong CYP3A4 inducers can result in decreased serum concentrations and loss of antimalarial efficacy"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mavacamten",
            "description": {
                "common": "enzalutamide will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "naloxegol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of naloxegol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.  Use of naloxegol with strong CYP3A4 inducers is not recommended"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nirmatrelvir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nirmatrelvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nirmatrelvir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir, a CYP3A4 substrate, is contraindicated with strong CYP3A4 inducers. Significantly reduced nirmatrelvir plasma concentrations may be associated with potential for loss of virologic response and possible resistance. Do not initiate nirmatrelvir/ritonavir immediately after discontinuing a strong 3A4 inducer owing to time needed for systemic clearance of the inducer."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers may reduce partiaprevir and ritonavir levels, and therefore decreased efficacy of Viekira Pak"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "panobinostat",
            "description": {
                "common": "enzalutamide decreases levels of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can reduce panobinostat levels by ~70% and lead to treatment failure."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "praziquantel",
            "description": {
                "common": "enzalutamide decreases levels of praziquantel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP450 inducers significantly decrease praziquantel blood levels."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "regorafenib",
            "description": {
                "common": "enzalutamide, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers decrease regorafenib levels and increase exposure of the active metabolite M-5."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abemaciclib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of abemaciclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of abemaciclib with strong CYP3A4 inducers reduces plasma concentration of abemaciclib and its metabolites."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of acalabrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of acalabrutinib with strong CYP3A inducers. If a strong CYP3A inducer must be used, increase acalabrutinib dose to 200 mg twice daily."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adagrasib",
            "description": {
                "common": "enzalutamide will increase the level or effect of adagrasib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alpelisib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of alpelisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of alpelisib (CYP3A4 substrate) with  strong CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amiodarone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amlodipine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "enzalutamide will decrease the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apremilast",
            "description": {
                "common": "enzalutamide will decrease the level or effect of apremilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong CYP inducers results in a significant decrease of systemic exposure of apremilast, which may result in loss of efficacy"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aprepitant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "armodafinil",
            "description": {
                "common": "enzalutamide will increase the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "avanafil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of axitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "enzalutamide will decrease the level or effect of bedaquiline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of bedaquiline with strong CYP3A4 inducers due to potential for decreased therapeutic effect"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bortezomib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosutinib",
            "description": {
                "common": "enzalutamide decreases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers decreased bosutinib plasma concentration by ~85% ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brigatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of brigatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong CYP3A4 inducers may decrease brigatinib efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabozantinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of cabozantinib with strong CYP3A4 inducers. If a strong CYP3A4 inducer is required, increase cabozantinib dose by 40 mg/day (Cometriq) or by 20 mg/day (Cabometyx). Resume previous dose 2-3 days after strong CYP3A4 inducer discontinued."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcitriol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of calcitriol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capmatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "enzalutamide decreases levels of ceritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of chlordiazepoxide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cilostazol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clorazepate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of clorazepate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "enzalutamide will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "copanlisib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of copanlisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of copanlisib with strong CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "enzalutamide decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dantrolene",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dantrolene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "daridorexant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of daridorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dasatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deflazacort",
            "description": {
                "common": "enzalutamide will decrease the level or effect of deflazacort by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.  Avoid coadministration of deflazacort with moderate or strong CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "delavirdine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dexlansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dihydroergotamine intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diltiazem",
            "description": {
                "common": "enzalutamide will decrease the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "docetaxel",
            "description": {
                "common": "enzalutamide will decrease the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxorubicin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxorubicin liposomal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of doxorubicin liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dronedarone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "duvelisib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of duvelisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with a strong CYP3A inducer decreases duvelisib area under the curve (AUC), which may reduce duvelisib efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elacestrant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of elacestrant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eliglustat",
            "description": {
                "common": "enzalutamide will decrease the level or effect of eliglustat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A inducers significantly decreases eliglustat exposure; coadministration not recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elvitegravir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of elvitegravir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration with CYP3A inducers may result in decreased plasma concentrations of elvitegravir and/or a concomitantly administered protease inhibitor and lead to loss of therapeutic effect and to possible resistance"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of encorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of entrectinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eplerenone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of erdafitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergotamine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erlotinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "enzalutamide will decrease the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "escitalopram",
            "description": {
                "common": "enzalutamide will decrease the level or effect of escitalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of esomeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estradiol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "enzalutamide will decrease the level or effect of estrogens conjugated synthetic by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estrogens esterified",
            "description": {
                "common": "enzalutamide will decrease the level or effect of estrogens esterified by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estropipate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eszopiclone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of eszopiclone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ethinylestradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ethosuximide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etoposide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of etoposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etravirine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "enzalutamide will decrease the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "exemestane",
            "description": {
                "common": "enzalutamide will decrease the level or effect of exemestane by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fedratinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fedratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Effect of coadministering a strong CYP3A4 inducer with fedratinib has not been studied."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "felbamate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of felbamate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "felodipine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "enzalutamide will increase the level or effect of fexinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. CYP450 inducers may significantly increase plasma concentrations of fexinidazole?s active metabolites: fexinidazole sulfoxide (M1) and fexinidazole sulfone (M2). M2 plasma concentrations associated with increased QT prolongation risks."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "finerenone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "flurazepam",
            "description": {
                "common": "enzalutamide will decrease the level or effect of flurazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fosaprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fostamatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ganaxolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ganaxolone with moderate or strong CYP3A4 inducers. If coadministration unavoidable, consider increasing ganaxolone dose; however, do not exceed maximum daily dose for weight."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glasdegib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of glasdegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of glasdegib with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of glecaprevir/pibrentasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of drugs that induce CYP3A4 with glecaprevir/pibrentasvir may decrease glecaprevir/pibrentasvir plasma concentrations. Potential for loss of therapeutic effect."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyprogesterone caproate (DSC)",
            "description": {
                "common": "enzalutamide will decrease the level or effect of hydroxyprogesterone caproate (DSC) by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "enzalutamide decreases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.  Strong CYP3A inducers decrease ibrutinib plasma concentrations by ~10-fold."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of idelalisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration; strong CYP3A4 inducers significantly decrease idelalisib systemic exposure"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "imatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infigratinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of infigratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "irinotecan",
            "description": {
                "common": "enzalutamide will decrease the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isradipine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "istradefylline",
            "description": {
                "common": "enzalutamide will decrease the level or effect of istradefylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of istradefylline with strong CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivabradine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ivacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ivosidenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of ivosidenib with strong CYP3A4 inducers decreased ivosidenib plasma concentrations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ixabepilone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ixazomib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ixazomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ixazomib with strong CYP3A inducers. Strong inducers have been shown to decrease ixazomib Cmax by 54% and AUC by 74%."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ketoconazole with strong CYP3A4 inducers from 2 weeks and during treatment with ketoconazole tablets. If use is unavoidable, monitor antifungal activity and increase ketoconazole if necessary."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lapatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lapatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of larotrectinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of larotrectinib with strong CYP3A4 inducers is unavoidable, double larotrectinib dose. Resume prior larotrectinib dose once CYP3A4 inducer discontinued for 3-5 half-lives"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lefamulin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lefamulin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of lefamulin with strong or moderate CYP3A inducers unless the benefit outweighs risks. Monitor for reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lemborexant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of leniolisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lomitapide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lomitapide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "losartan",
            "description": {
                "common": "enzalutamide will decrease the level or effect of losartan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lovastatin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumateperone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lumateperone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lurasidone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lurasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lurbinectedin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of lurbinectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of macimorelin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potential for false positive test results if macimorelin and strong CYP3A4 inducers are coadministered. Discontinue strong CYP3A4 inducer, allowing for sufficient washout time, before testing."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macitentan",
            "description": {
                "common": "enzalutamide will decrease the level or effect of macitentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministering macitentan with strong CYP3A4 inducers "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "maraviroc",
            "description": {
                "common": "enzalutamide will decrease the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "marijuana",
            "description": {
                "common": "enzalutamide will decrease the level or effect of marijuana by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mefloquine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mestranol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methadone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midazolam",
            "description": {
                "common": "enzalutamide will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midostaurin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations resulting in reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of mobocertinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "naldemedine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of naldemedine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with strong CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neratinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of neratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of neratinib with strong/moderate CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "enzalutamide will decrease the level or effect of netupitant/palonosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Netupitant is mainly metabolized by CYP3A4; avoid use in patients who are chronically using a strong CYP3A4 inducer"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nilotinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nimodipine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norethindrone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of norethindrone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration unless benefit outweighs risk. When coadministered, hormonal contraceptives are not a reliable method of effective birth control. Concomitant use may increase incidence of menstruation associated adverse effects (amenorrhea, dysmenorrhea, menorrhagia)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norethindrone acetate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of norethindrone acetate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration unless benefit outweighs risk. When coadministered, hormonal contraceptives are not a reliable method of effective birth control. Concomitant use may increase incidence of menstruation associated adverse effects (amenorrhea, dysmenorrhea, menorrhagia)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norethindrone transdermal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of norethindrone transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration unless benefit outweighs risk. When coadministered, hormonal contraceptives are not a reliable method of effective birth control. Concomitant use may increase incidence of menstruation associated adverse effects (amenorrhea, dysmenorrhea, menorrhagia)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norgestrel",
            "description": {
                "common": "enzalutamide will decrease the level or effect of norgestrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olaparib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olutasidenib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of olutasidenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong or moderate CYP3A inducers decrease olutasidenib (a CYP3A4 substrate) plasma concentrations and efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of omaveloxolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omeprazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of omeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ondansetron",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "osimertinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of osimertinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of osimertinib with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palbociclib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A inducers decrease palbociclib plasma exposure by ~85%."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pazopanib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pemigatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pemigatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perampanel",
            "description": {
                "common": "enzalutamide will decrease the level or effect of perampanel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pexidartinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pomalidomide",
            "description": {
                "common": "enzalutamide decreases levels of pomalidomide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponatinib",
            "description": {
                "common": "enzalutamide decreases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid unless the coadministration outweighs the possible risk of ponatinib underexposure; monitor for signs of reduced efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pralsetinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pretomanid by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Pretomanid is a CYP3A4 substrate. Avoid coadministration of strong or moderate CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primaquine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of primaquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "progesterone intravaginal gel",
            "description": {
                "common": "enzalutamide will decrease the level or effect of progesterone intravaginal gel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "progesterone micronized",
            "description": {
                "common": "enzalutamide will decrease the level or effect of progesterone micronized by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "progesterone, natural",
            "description": {
                "common": "enzalutamide will decrease the level or effect of progesterone, natural by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quetiapine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ranolazine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ribociclib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ribociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of ribociclib with strong CYP3A inducers should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.  If unavoidable, increase enzalutamide dose from 160 mg to 240 mg qDay. Once strong CYP3A4 inducer is discontinued, return enzalutamide dose to the dose used before initiating strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Consider using an alternant that has no or minimal CYP3A4 induction potential when possible. If unavoidable, increase enzalutamide dose from 160 mg qDay to 240 mg qDay. If a strong CYP3A4 inducer is discontinued, return enzalutamide dose to dose used before initiating the strong CY"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.  If unavoidable, increase enzalutamide dose from 160 mg qDay to 240 mg qDay. If a CYP3A4 inducer is discontinued, return enzalutamide dose to dose used before initiating the CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rimegepant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of rimegepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ripretinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ripretinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with a strong CYP3A inhibitor will decrease systemic exposure to ripretinib and its active metabolite (DP-5439), which may decrease risk of adverse reactions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "enzalutamide will decrease the level or effect of rivaroxaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "roflumilast",
            "description": {
                "common": "enzalutamide will decrease the level or effect of roflumilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rolapitant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of rolapitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Long-term coadministration of strong CYP3A4 inducers with rolapitant may significantly decrease rolapitant efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "romidepsin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selpercatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of selpercatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selumetinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of selumetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "simvastatin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "enzalutamide will decrease the level or effect of siponimod by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with a drug that causes moderate CYP2C9 plus a moderate or strong CYP3A4 inducer is not recommended. Coadministration with moderate or strong CYP3A4 inducers alone is not recommended for patients with CYP2C9*1/*3 and*2/*3 genotype."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sofosbuvir/velpatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Velpatasvir is a substrate of CYP2B6, CYP2C8, and CYP3A4. Drugs that are moderate-to-potent inducers of CYP2B6, CYP2C8, or CYP3A4 may significantly decrease velpatasvir plasma concentrations, leading to potentially reduced therapeutic effect."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sonidegib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sonidegib with strong or moderate CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sorafenib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sotorasib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sparsentan",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sparsentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "stiripentol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of stiripentol by  Other (see comment). Avoid or Use Alternate Drug. Enzalutamide is a strong CYP3A4/CYP2C19 inducer. Stiripentol is a CYP3A4/CYP2C19 substrate. If unable to avoid coadministration, monitor closely and consider stiripentol dose increase if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sunitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tadalafil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "enzalutamide decreases effects of tamoxifen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. affecting hepatic/intestinal enzyme CYP3A4 metabolism. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tamsulosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "enzalutamide will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetracycline",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tetracycline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tezacaftor",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tezacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ticagrelor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ticlopidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tivozanib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tivozanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tolterodine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "toremifene",
            "description": {
                "common": "enzalutamide will decrease the level or effect of toremifene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trabectedin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of trabectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tucatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ubrogepant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ubrogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ulipristal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of upadacitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valbenazine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of valbenazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Concomitant use not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vandetanib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of vandetanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "velpatasvir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of velpatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of vemurafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "venetoclax",
            "description": {
                "common": "enzalutamide will decrease the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of venetoclax with strong or moderate CYP3A inducers. Consider alternative treatment with agents that have less CYP3A induction."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vinblastine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vincristine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vincristine liposomal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of vincristine liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voclosporin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of voclosporin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vonoprazan",
            "description": {
                "common": "enzalutamide will decrease the level or effect of vonoprazan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "enzalutamide decreases levels of vorapaxar by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of vortioxetine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "enzalutamide will decrease the level or effect of voxelotor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor is primarily metabolized by CYP3A4. Avoid coadministration with moderate or strong CYP3A4 inducers. If unable to avoid coadministration, increase voxelotor dose (see Dosage Modifications)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxilaprevir",
            "description": {
                "common": "enzalutamide will decrease the level or effect of voxilaprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of zanubrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zolpidem",
            "description": {
                "common": "enzalutamide will decrease the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abiraterone",
            "description": {
                "common": "enzalutamide decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Recommended atogepant dosage with concomitant use of strong or moderate CYP3A4 inducers is 30 mg or 60 mg qDay."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avatrombopag",
            "description": {
                "common": "enzalutamide will decrease the level or effect of avatrombopag by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. When treating ITP, coadministration of avatrombopag with a moderate or strong dual CYP2C9/3A4 inducer requires an increased avatrombopag starting dose. Refer to drug monograph for specific recommendations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belumosudil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of belumosudil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase belumosudil dosage to 200 mg PO BID when coadministered with strong CYP3A inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "enzalutamide will decrease the level or effect of benzhydrocodone/acetaminophen by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brentuximab vedotin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of brentuximab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of brexpiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Double brexpiprazole dose over 1-2 weeks if administered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of buprenorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of buprenorphine buccal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of buprenorphine subdermal implant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inducer for signs and symptoms of withdrawal. If the dose of the concomitant CYP3A4 inducer cannot be reduced or discontinued, implant removal may be necessary and the patient should then be treated with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inducer is discontinued in a patient who has been stabilized on buprenorphine, monitor the patient for overmedication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of buprenorphine transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "enzalutamide will decrease the level or effect of buprenorphine, long-acting injection by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Patients who transfer to buprenorphine long-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inducers should be monitored to ensure buprenorphine plasma levels are adequate. If the buprenorphine dose is inadequate and the CYP3A4 inducer cannot be reduced or discontinued, transition the patient back to a buprenorphine formulation that permits dose adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buspirone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcifediol",
            "description": {
                "common": "enzalutamide, calcifediol. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Drugs that stimulate microsomal hydroxylation reduce the half-life of calcifediol."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider an increase in cannabidiol dosage (based on clinical response and tolerability) when coadministered with a strong CYP3A4 inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of chloroquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "enzalutamide will decrease the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "enzalutamide will decrease the level or effect of clonazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cobicistat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "enzalutamide will decrease the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of diazepam intranasal by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Strong or moderate CYP2C19 inducers may increase rate of diazepam elimination; therefore, efficacy of diazepam may be decreased."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronabinol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of dronabinol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dronabinol is a CYP3A4 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "enzalutamide will decrease the level or effect of elagolix by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, enzalutamide. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enfortumab vedotin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of enfortumab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of erdafitinib by  affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. If a moderate CYP2C9 inducer must be coadministered, administer 8-mg/day dose initially, with potential to increase to 9 mg/day based on serum phosphate levels on Days 14-21 and tolerability. If a moderate CYP2C9 inducer must be coadministered after the initial dose increase period based on serum phosphate levels and tolerability, increase erdafitinib dose up to 9 mg. When a moderate inducer discontinued, continue erdafitinib at same dose, in absence of drug-related toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol vaginal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of estradiol vaginal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fentanyl intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fentanyl transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "enzalutamide will decrease the level or effect of fentanyl transmucosal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inducers substantially decrease flibanserin systemic exposure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gallium Ga 68 PSMA-11",
            "description": {
                "common": "enzalutamide will decrease the level or effect of gallium Ga 68 PSMA-11 by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Androgen deprivation therapy and other therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 in prostate cancer. The effect of ADT on the performance of gallium Ga 68 PSMA-11 is unknown."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gefitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of gefitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase gefitinib to 500 mg daily if coadministered with a strong CYP3A4 inducer.  Resume gefitinib dose at 250 mg/day 7 days after discontinuing the strong inducer."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "guanfacine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of guanfacine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong or moderate CYP3A4 inducers significantly reduce guanfacine plasma concentrations and elimination half-life. If coadministered, more frequent dosing of the IR product may be required to achieve or maintain the desired hypotensive response. For patients with ADHD, FDA-approved labeling for ER guanfacine recommends that, if coadministered, doubling the recommended dose of guanfacine should be considered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of haloperidol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "enzalutamide increases toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inducers may increase the metabolism of ifosfamide to its active alkylating metabolites. CYP3A4 inducers may increase the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levamlodipine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of levamlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No information is available on the quantitative effects of CYP3A4 inducers on amlodipine. Closely monitor blood pressure when amlodipine is coadministered with CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "enzalutamide decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "enzalutamide decreases levels of levonorgestrel oral by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "enzalutamide will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "linagliptin",
            "description": {
                "common": "enzalutamide will increase the level or effect of linagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a CYP3A4 inducer"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "medroxyprogesterone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of medroxyprogesterone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Contraceptirve failure possible. Use alternative if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of mirtazapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of enzalutamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "modafinil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of modafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "montelukast",
            "description": {
                "common": "enzalutamide will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nevirapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of oliceridine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. If coadministration with a CYP3A4 inducer is necessary, consider increasing oliceridine dose until stable drug effects are achieved; monitor for signs of opioid withdrawal. If inducer is discontinued, consider oliceridine dosage reduction and monitor for signs of respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "enzalutamide will decrease the level or effect of osilodrostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor cortisol concentration and patient?s signs and symptoms during coadministration or discontinuation with strong CYP3A4 inducers. Adjust dose of osilodrostat if necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ospemifene",
            "description": {
                "common": "enzalutamide decreases levels of ospemifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "enzalutamide decreases levels of oxycodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "enzalutamide will decrease the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "enzalutamide will decrease the level or effect of paclitaxel protein bound by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pimavanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid coadministration if possible. Monitor for reduced pimavanserin efficacy. An increase in pimavanserin dosage may be needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitolisant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pitolisant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Pitolisant exposure is decreased by 50% if coadministered with strong CYP3A4 inducers. For patients stable on pitolisant 8.9 mg/day or 17.8 mg/day, double the pitolisant dose (ie, 17.8 mg or 35.6 mg, respectively) over 7 days. If the strong CYP3A4 inducer is discontinued, reduce pitolisant dosage by half."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polatuzumab vedotin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of polatuzumab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Polatuzumab undergoes catabolism to small peptides, amino acids, monomethyl auristatin E (MMAE), and unconjugated MMAE-related catabolites. MMAE is a CYP3A4 substrate. Coadministration of polatuzumab vedotin with a strong CYP3A4 inducer may decrease unconjugated MMAE AUC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quazepam",
            "description": {
                "common": "enzalutamide will decrease the level or effect of quazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of rifabutin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "riociguat",
            "description": {
                "common": "enzalutamide will decrease the level or effect of riociguat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Data not available for dose adjustment"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "enzalutamide will decrease the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sildenafil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and enzalutamide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, enzalutamide. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "enzalutamide decreases effects of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of CYP3A4 inducers may decrease sufentanil levels and efficacy, possibly precipitating withdrawal syndrome in patients who have developed physical dependence to sufentanil. Discontinuation of  concomitantly used CYP3A4 inducers may  increase sufentanil plasma concentration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "suvorexant",
            "description": {
                "common": "enzalutamide will decrease the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inducers may decrease suvorexant efficacy; if increased suvorexant dose required, do not exceed 20 mg/day"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus ointment",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tacrolimus ointment by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tasimelteon",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tasimelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid coadministration of tasimelteon with strong CYP3A4 inducers"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will increase the level or effect of enzalutamide by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teniposide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of teniposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbinafine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of terbinafine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teriflunomide",
            "description": {
                "common": "teriflunomide increases levels of enzalutamide by Other (see comment). Use Caution/Monitor. \nComment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiagabine",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tiagabine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tofacitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Loss of, or decreased response to tofacitinib may occur when coadministered with potent CYP3A4 inducers"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "enzalutamide will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "enzalutamide will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "enzalutamide will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "enzalutamide will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vilazodone",
            "description": {
                "common": "enzalutamide decreases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider increasing vilazodone dose up to 2-fold (not to exceed 80 mg/day) when coadministered with strong CYP3A4 inducers for >14 days."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "enzalutamide will decrease the level or effect of voriconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "enzalutamide decreases levels of vortioxetine by increasing metabolism. Modify Therapy/Monitor Closely. Consider increasing the vortioxetine dose when coadministered with strong CYP inducers for >14 days; not to exceed 3 times original vortioxetine dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "enzalutamide will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zonisamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Asthenic conditions",
            "percent": "47-51"
        },
        {
            "name": "Back pain",
            "percent": "26-29"
        },
        {
            "name": "Constipation",
            "percent": "23"
        },
        {
            "name": "Diarrhea",
            "percent": "22"
        },
        {
            "name": "Arthralgia",
            "percent": "21"
        },
        {
            "name": "Hot flush",
            "percent": "18-20"
        },
        {
            "name": "Decreased appetite",
            "percent": "19"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "16"
        },
        {
            "name": "Peripheral edema",
            "percent": "12-15"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "15"
        },
        {
            "name": "Hypertension",
            "percent": "6.4-14"
        },
        {
            "name": "Falls",
            "percent": "4.6-13"
        },
        {
            "name": "Headache",
            "percent": "11-12"
        },
        {
            "name": "Decreased weight",
            "percent": "12"
        },
        {
            "name": "Dyspnea",
            "percent": "11"
        },
        {
            "name": "Dizziness",
            "percent": "9.5-11"
        },
        {
            "name": "Muscular weakness",
            "percent": "9.8"
        },
        {
            "name": "Insomnia",
            "percent": "8.2-8.8"
        },
        {
            "name": "Hematuria",
            "percent": "6.9-8.8"
        },
        {
            "name": "Nonpathologic fractures",
            "percent": "4-8.8"
        },
        {
            "name": "Lower respiratory tract and lung infection",
            "percent": "7.9-8.5"
        },
        {
            "name": "Dysgeusia",
            "percent": "7.6"
        },
        {
            "name": "Spinal cord compression and cauda equina syndrome",
            "percent": "7.4"
        },
        {
            "name": "Anxiety",
            "percent": "6.5"
        },
        {
            "name": "Pollakiuria",
            "percent": "4.8"
        },
        {
            "name": "Pruritus",
            "percent": "3.8"
        },
        {
            "name": "Dry skin",
            "percent": "3.5"
        },
        {
            "name": "Epistaxis",
            "percent": "3.3"
        },
        {
            "name": "Asthenic conditions",
            "percent": "3.4-9"
        },
        {
            "name": "Hypertension",
            "percent": "7.2"
        },
        {
            "name": "Spinal cord compression and cauda equina syndrome",
            "percent": "6.6"
        },
        {
            "name": "Paresthesia",
            "percent": "6.6"
        },
        {
            "name": "Back pain",
            "percent": "2.5-5.3"
        },
        {
            "name": "Mental impairment disorders",
            "percent": "4.3-5.7"
        },
        {
            "name": "Hypoesthesia",
            "percent": "4"
        },
        {
            "name": "Gynecomastia",
            "percent": "3.4"
        },
        {
            "name": "Arthralgia",
            "percent": "1.6-2.5"
        },
        {
            "name": "Lower respiratory tract and lung infection",
            "percent": "1.5-2.4"
        },
        {
            "name": "Hypertension",
            "percent": "2.1"
        },
        {
            "name": "Restless leg syndrome",
            "percent": "2.1"
        },
        {
            "name": "Nonpathologic fractures",
            "percent": "1.4-2.1"
        },
        {
            "name": "Hematuria",
            "percent": "1.3-1.8"
        },
        {
            "name": "Falls",
            "percent": "0.3-1.6"
        },
        {
            "name": "Muscular weakness",
            "percent": "1.5"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "1.3"
        },
        {
            "name": "Diarrhea",
            "percent": "0.3-1.1"
        },
        {
            "name": "Peripheral edema",
            "percent": "0.2-1"
        },
        {
            "name": "Headache",
            "percent": "0.2-0.9"
        },
        {
            "name": "Decreased weight",
            "percent": "0.8"
        },
        {
            "name": "Constipation",
            "percent": "0.7"
        },
        {
            "name": "Dyspnea",
            "percent": "0.6"
        },
        {
            "name": "Dizziness",
            "percent": "0.3-0.5"
        },
        {
            "name": "Mental impairment disorders",
            "percent": "0.3"
        },
        {
            "name": "Hypoesthesia",
            "percent": "0.3"
        },
        {
            "name": "Anxiety",
            "percent": "0.3"
        },
        {
            "name": "Decreased appetite",
            "percent": "0.3"
        },
        {
            "name": "Epistaxis",
            "percent": "0.1"
        },
        {
            "name": "Hot flush",
            "percent": "0.1"
        },
        {
            "name": "Dysgeusia",
            "percent": "0.1"
        },
        {
            "name": "Restless leg syndrome",
            "percent": "0.1"
        },
        {
            "name": "Insomnia",
            "percent": "0.1"
        }
    ]
}